Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong
Introduction
Varicella zoster virus causes herpes zoster (HZ) upon reactivation in patients who were previously infected in earlier stage of life. HZ manifestations include severe pain, followed by vesicles along the dermatome(s). Truck, head and neck are most commonly affected, while ophthalmic complications are also common. Post-herpetic neuralgia (PHN), referring to the pain that persisted beyond the acute phase of HZ, also frequently occurs. Epidemiologic findings suggested that one-third of Chinese population developed HZ within their lifetime and the incidence increased with age from 5.18 cases per 1000 people at 40–50 years old to 11.77 cases per 1000 in those above 70 years old. Hospitalizations and medical cost per HZ patient also increased with age [1]. Population census ranked Hong Kong to be one of the cities with longest life-expectancy. The life expectancies at birth for men and women were 81 years and 87 years, respectively, and 54% of seven millions were females and the ≥50 years age groups accounted for 40% of the entire population in 2016 [2]. With increasing size of aging population, it is anticipated that the HZ prevalence will increase over time in Hong Kong.
A live-attenuated vaccine against HZ was first available in 2006 for adults aged 60 years and older, was later approved by Food and Drug Administration (FDA) in 2011 for adults aged 50 years and older. The live-attenuated vaccine reduced HZ cases by 51% and PHN cases by 67% for adults aged 60 years or older [3]. Further age-stratified clinical findings showed that the vaccine efficacy against HZ in elderly aged 70 years (38%) or older was significantly lower than the efficacy (70%) in the 50–59 years age group [3], [4].
Adjuvanted HZ subunit vaccine was recently approved in 2017 by the FDA for adults aged 50 years. Clinical trials data found the overall vaccine efficacy against the HZ incidence for adults aged 50 years and older to be 97% [5]. The efficacy for age groups 50–59, 60–69, 70–79 and ≥80 years were above 90% [5], [6]. The Advisory Committee on Immunization Practices (ACIP) recommended it for healthy adults aged 50 years and older and for adults who had previously vaccinated with the live-attenuated HZ vaccine [7].
With aging population and prolonging life expectancy, the adult population at risk for HZ is high in Hong Kong. Universal varicella vaccination was implemented in children vaccination program subsidized by the Hong Kong government in 2014 and possibly reduced the exogenous boosting effect used to be available from those shedding zoster virus in the community. The adult vaccination program subsidized by government currently does not include zoster vaccine. To assist the decision-making process of public healthcare providers and the government on the implementation of HZ subunit vaccine in Hong Kong vaccination program, this study therefore aimed to investigate the cost-effectiveness of HZ subunit vaccine for older adults at different age from the perspective of Hong Kong society.
Section snippets
Model design
A Markov model was designed to simulate the potential life-long economic and clinical outcomes of zoster vaccination in a hypothetical cohort of immunocompetent older adults and have with no contraindications for HZ subunit vaccine. The age of hypothetical cohort was 50 years old at the entry of model. Four vaccination strategies were examined: (1) Vaccination at entry of model (vaccination at age 50 years), (2) no vaccination for next 10 years and vaccinated at age 60 years (defer vaccination
Base-case analysis
In the base-case analysis (Table 2), all vaccination strategies reduced the incidence of HZ and PHN and saved QALYs at higher total costs. The HZ and PHN incidence and QALY loss over the time horizon of Markov model (50 years) for each vaccination strategies were showed in Fig. 2a–c. Comparing with no vaccination, vaccination at age 50 years was the most effective strategy with the highest QALYs saved and additional total cost (0.00258; USD166), followed by deferring vaccination to age 60 years
Discussion
The present study examined the potential cost-effectiveness of three vaccination strategies with HZ subunit 2-dose vaccine for 50 years old adults. Our base-case analysis results showed that all three vaccination strategies saved QALYs at higher cost, and the base-case findings were supported by the one-way and probabilistic sensitivity analyses.
Four influential factors were common to the three vaccination strategies: Cost of 2-dose HZ subunit vaccine, yearly waning rate of 2-dose vaccine
Conflict of interest
All authors have no conflict of interest.
Funding
This study was supported by Health and Medical Research Fund (project number 15140432), Food and Health Bureau, The Government of the Hong Kong SAR, China.
References (26)
- et al.
Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan
Vaccine
(2010) - et al.
Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey
J Pain
(2005) - Census and Statistics Department, Hong Kong SAR. Women and men in Hong Kong key statistics 2017 Edition. Website:...
- et al.
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
N Engl J Med
(2005) - et al.
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years
Clin Infect Dis
(2012) - et al.
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults
N Engl J Med
(2015) - et al.
Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older
N Engl J Med
(2016) - Centers for Disease Control and Prevention. Singles (Herpes Zoster) vaccination. Website:...
- The World Bank. GDP per capital (current US$) Data. Website: Cap. <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD>...
- World Health Organization. Global Health Observatory (GHO) data. Website:...
Herpes zoster in Germany: quantifying the burden of disease
BMC Infect Dis
Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006
Acta Derm Venereol
Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up
BMJ
Cited by (12)
Cost-Effectiveness of Recombinant Zoster Vaccine for Adults Aged ≥50 Years in China
2023, American Journal of Preventive MedicineCost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
2023, Human Vaccines and ImmunotherapeuticsPublic health impact of herpes zoster vaccination on older adults in Hong Kong
2023, Human Vaccines and ImmunotherapeuticsSystematic review of health economic evaluation studies on new herpes zoster vaccine among elderly
2022, Journal of Current Science and TechnologyCall for attention to the standardized management of herpes zoster
2022, National Medical Journal of China